Summary

Compliant asthmatic patients are significantly less likely to undergo an exacerbation than their less-compliant counterparts [1^]. Studies have shown that patient adherence can already be significantly increased by text message reminders ^[2]. Different connected drug delivery systems have been introduced in the respiratory arena in the last years. For example Cohero’s platform in connection with their Herotracker and H&T Presspart’s eMDI or the solutions of Propeller Health or Adherium. These systems use a sensor to detect usage pattern of inhalers, e.g. metered dose inhalers, dry powder inhalers or nebulizers, and transmit these patterns to hosts, for example mobile phones. Based on the collected information patients can be engaged and their adherence increases. These systems therefore have the ability to improve patient outcomes significantly. The resulting value creates opportunities for the different stakeholders in the health system – pharmaceutical industry, regulators, physicians, insurance companies, patients. The use of these and other electronic monitoring devices (EMDs) is becoming increasingly prevalent in clinical practice to harness cutting edge technology to achieve improved disease control and medication adherence. The systems described above offer extensive potential in both the clinical trials and clinical care environments. Especially in connection with lung function measurement devices, for example Cohero’s Spirometer, electronic data capture can furthermore drive improved clinical decision making and overall care management for the pulmonary community.